The U.S. Medical Device Excise Tax continues to draw scorn from industry advocates as a jobs killer. However, new data from a survey tells a different story about how executives are compensating for costs of the tax, and that story varies considerably by size of company.
Will the device tax be repealed? What are its implications under the 114th Congress? This primer provides some answers.